Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Insights
  3. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • NHS Solutions
  • Life Sciences Industry
  • Advancing UK Healthcare
  • Pharmacy Communications
NHS Solutions

Utilising the extensive range of data assets exclusively available to IQVIA, combined with our market leading expertise, we are able to support the NHS meet the challenge of delivering high quality, efficient and cost effective healthcare by identifying actionable insight and realising the value in data.

Learn More
NHS Solutions
Life Sciences Industry

We believe in the UK’s potential to become a global leader in the life sciences sector, and our investments announced in the 2018 Second Life Sciences Sector Deal further support the UK Government and the industry’s aim to make that potential a reality.

Learn More
Life Sciences Industry Solutions
Advancing UK Healthcare

We are committed to providing solutions that inform and enable all stakeholders across UK healthcare, to innovate with confidence, maximise opportunities, and, ultimately, drive human health outcomes forward.

Learn More
Advancing UK Healthcare Solutions
Pharmacy Communications

IQVIA’s Pharmacy Communications offers pharma companies a simple and cost-effective channel to communicate product changes, updates and patient advice directly to patients via pharmacists.

Learn More
MAIN/Insights
Insights/
BLOGS, WHITEPAPERS & CASE STUDIES

Explore our library of resources spanning the healthcare & life science ecosystem on the latest topics, trends, and market developments that matter to you.

Learn More
NEWSROOM

Stay up to date on the latest news and press releases from IQVIA UK & Ireland.

Learn More

Report

"Our commitment to sustainability.

Learn More
MAIN/Contact Us
Contact Us/

Information for Members of the Public

Research using non-identified patient data is driving healthcare forward and improving patient outcomes.

Medical research is essential for improving healthcare and tackling the biggest health problems that we face today. Whether you are healthy or have a medical condition, medical research benefits everyone by improving doctors’ and scientists’ understanding of how well different treatments and medicines work.

There are many ways in which medical research is conducted. Clinical trials, which are used to test new medicines in a controlled setting, are one example that many people may be familiar with, but there is much more to medical research than clinical trials. Medical research is increasingly being carried out using health data as a complement to traditional clinical trials to understand what is happening to patients when they are treated in real life settings. Health information collected on patients, when they are prescribed a medicine or visit their doctor, can be used to conduct medical research into the effectiveness of a particular treatment or to detect harmful side effects of a medicine.

Hospital Treatment Insights Service (HTI)
IQVIA is currently working with a number of hospital trusts in England to collect information on illness and medicines prescribed in hospitals. This data is used to describe how medicines are being used and to conduct studies to monitor the use, effectiveness and safety of medicines when treating diseases.

IQVIA™ Medical Research Data 
Non-identified longitudinal data collected from GP practices in the UK are an invaluable medical research resource that enables a patient’s journey to be tracked from the initial consultation and investigation and through referral to diagnosis of a condition and treatment. Chronic conditions, in particular, require a long history of data so that trends and signals can be detected and early risk prediction tools can be designed. Availability of sufficient data and research can drive health policy changes or adoption of new guidelines for healthcare providers, thus leading to improved outcomes for patients.

Hospital Episode Statistics (HES)
Non-identified details of all admissions, A and E attendances and outpatient appointments at NHS hospitals in England.

National Amyloidosis Centre (NAC) - Hospital Episode Statistics (HES) Data
 Amyloidosis patients often go undiagnosed for a long period of time, with patients requiring multiple hospital visits before they are finally diagnosed. There are still large gaps of knowledge about amyloidosis. Linking NAC´s data and HES data, non-identified information is used to support researchers in generating a better understanding about amyloidosis and to improve diagnosis and treatment for NHS patients affected by this condition.

Sheffield Teaching Hospitals NHS Foundation Trust (STHFT)
Medical information of patients with Pulmonary Arterial Hypertension (PH) have been added to a database being used for research purposes in PH. The reason of this research was to help NHS and its partners to make informed decisions about the future development of specialist services for PH. Additionally, this helped STHFT to develop new approaches to diagnosing and treating PH, including supporting the development of new drug discovery in partnership with pharmaceutical companies. IQVIA Solutions UK Limited, STHFT and Janssen Pharmaceuticals were the data controllers of the STHFT-HES data, and Janssen were the funders of the study. The study has now been finalized, and the findings are pending to be published.

Sheffield Teaching Hospital NHS Foundation Trust (STHFT)
Medical information of patients with Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), and Sarcoidosis-Associated Pulmonary Hypertension (SAPH) have been used to carry out a retrospective real world data analysis in Pulmonary Hypertension (PH) using STHFT-HES data. The reason of this research was that due to the complexity, late diagnosis and absence of real world studies across all subtypes of PH, there is currently a lack of understanding regarding the clinical pathway leading to diagnosis. In addition, there is a need to further explore, and study post-diagnosis pathways and patient related outcomes associated with these diseases in routine clinical practice. The study focused on describing and comparing PAH, CTEPH, and SAPH populations in terms of characteristics of patients, clinical pathways pre-diagnosis and diagnostic procedures, treatment patterns post diagnosis, clinical outcomes, and Healthcare Resource Utilisation (HCRU). IQVIA Solutions UK Limited, IQVIA Technology Services Limited, and Janssen Pharmaceuticals were the data controllers of the STHFT-HES data, and Janssen were the funders of the study. The study has now been finalized, and the findings are pending to be published.

Contact Us